Literature DB >> 22674478

Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.

Nils D Arvold1, Rinaa S Punglia, Melissa E Hughes, Wei Jiang, Stephen B Edge, Sara H Javid, Christine Laronga, Joyce C Niland, Richard L Theriault, Jane C Weeks, Yu-Ning Wong, Sandra J Lee, Michael J Hassett.   

Abstract

BACKGROUND: The number of women diagnosed with ductal carcinoma in situ (DCIS) is increasing. Although many eventually develop a second breast cancer (SBC), little is known about the characteristics of SBCs. The authors described the characteristics of SBC and examined associations between the pathologic features of SBC and index DCIS cases.
METHODS: Women were identified in the National Comprehensive Cancer Network Outcomes Database who were diagnosed with DCIS from 1997 to 2008 and underwent lumpectomy and who subsequently developed SBC (including DCIS or invasive disease that occurred in the ipsilateral or contralateral breast). The Fisher exact test and the Spearman test were used to examine associations between the pathologic characteristics of SBC and index DCIS cases.
RESULTS: Among 2636 women who underwent lumpectomy for DCIS, 150 (5.7%) experienced an SBC after a median of 55.5 months of follow-up. Of these 150 women, 105 (70%) received adjuvant radiotherapy, and 50 (33.3%) received tamoxifen for their index DCIS. SBCs were ipsilateral in 54.7% of women and invasive in 50.7% of women. Among the index DCIS cases, 60.6% were estrogen receptor (ER)-positive, and 54% were high grade, whereas 77.5% of SBCs were ER-positive, and 48.2% were high grade. Tumor grade (P = .003) and ER status (P = .02) were associated significantly between index DCIS and SBC, whereas tumor size was not (P = .87).
CONCLUSIONS: After breast conservation for DCIS, SBC in either breast exhibited pathologic characteristics similar to the index DCIS, suggesting that women with DCIS may be at risk for developing subsequent breast cancers of a similar phenotype.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22674478      PMCID: PMC3496800          DOI: 10.1002/cncr.27691

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

1.  Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast.

Authors:  Grace L Smith; Benjamin D Smith; Bruce G Haffty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-05       Impact factor: 7.038

2.  The management of ductal carcinoma in situ of the breast: a screened population-based analysis.

Authors:  Eileen Rakovitch; Jean-Philippe Pignol; Carole Chartier; Wedad Hanna; Hariette Kahn; John Wong; Verna Mai; Lawrence Paszat
Journal:  Breast Cancer Res Treat       Date:  2006-07-13       Impact factor: 4.872

3.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Authors:  Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers
Journal:  J Clin Oncol       Date:  2006-06-26       Impact factor: 44.544

4.  Results of 23,810 cases of ductal carcinoma-in-situ.

Authors:  William E Sumner; Leonidas G Koniaris; Sarah E Snell; Seth Spector; Jodeen Powell; Eli Avisar; Frederick Moffat; Alan S Livingstone; Dido Franceschi
Journal:  Ann Surg Oncol       Date:  2007-01-24       Impact factor: 5.344

5.  Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden.

Authors:  F Wärnberg; J Bergh; L Holmberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-09       Impact factor: 4.254

6.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

Authors:  E R Fisher; J Dignam; E Tan-Chiu; J Costantino; B Fisher; S Paik; N Wolmark
Journal:  Cancer       Date:  1999-08-01       Impact factor: 6.860

7.  Effectiveness of radiation therapy in older women with ductal carcinoma in situ.

Authors:  Benjamin D Smith; Bruce G Haffty; Thomas A Buchholz; Grace L Smith; Deron H Galusha; Justin E Bekelman; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

8.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening.

Authors:  Stefan O Emdin; Bengt Granstrand; Anita Ringberg; Kerstin Sandelin; Lars-Gunnar Arnesson; Hans Nordgren; Harald Anderson; Hans Garmo; Lars Holmberg; Arne Wallgren
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

9.  Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.

Authors:  Tina W F Yen; Henry M Kuerer; Rebecca A Ottesen; Layla Rouse; Joyce C Niland; Stephen B Edge; Richard L Theriault; Jane C Weeks
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

10.  An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ.

Authors:  Stephanie G MacAusland; Jaroslaw T Hepel; Frank K Chong; Shira L Galper; Jennifer S Gass; Robin Ruthazer; David E Wazer
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

View more
  6 in total

1.  Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.

Authors:  N Sänger; K Engels; A Graf; E Ruckhäberle; K E Effenberger; T Fehm; U Holtrich; S Becker; T Karn
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-11       Impact factor: 2.915

2.  DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.

Authors:  R Souchon; M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-01       Impact factor: 3.621

3.  Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Authors:  Michael J Hassett; Wei Jiang; Laurel A Habel; Larissa Nekhlyudov; Ninah Achacoso; Luana Acton; Stuart J Schnitt; Deb Schrag; Rinaa S Punglia
Journal:  Breast Cancer Res Treat       Date:  2016-02-03       Impact factor: 4.872

4.  Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study.

Authors:  Yasuaki Sagara; Rachel A Freedman; Ines Vaz-Luis; Melissa Anne Mallory; Stephanie M Wong; Fatih Aydogan; Stephen DeSantis; William T Barry; Mehra Golshan
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

5.  Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.

Authors:  Hyeonyoung Ko; Jinyoung Shin; Jeong Eon Lee; Seok Jin Nam; Tuong Linh Nguyen; John Llewelyn Hopper; Yun-Mi Song
Journal:  BMC Cancer       Date:  2017-12-05       Impact factor: 4.430

6.  Genetic predisposition to ductal carcinoma in situ of the breast.

Authors:  Christos Petridis; Mark N Brook; Vandna Shah; Kelly Kohut; Patricia Gorman; Michele Caneppele; Dina Levi; Efterpi Papouli; Nick Orr; Angela Cox; Simon S Cross; Isabel Dos-Santos-Silva; Julian Peto; Anthony Swerdlow; Minouk J Schoemaker; Manjeet K Bolla; Qin Wang; Joe Dennis; Kyriaki Michailidou; Javier Benitez; Anna González-Neira; Daniel C Tessier; Daniel Vincent; Jingmei Li; Jonine Figueroa; Vessela Kristensen; Anne-Lise Borresen-Dale; Penny Soucy; Jacques Simard; Roger L Milne; Graham G Giles; Sara Margolin; Annika Lindblom; Thomas Brüning; Hiltrud Brauch; Melissa C Southey; John L Hopper; Thilo Dörk; Natalia V Bogdanova; Maria Kabisch; Ute Hamann; Rita K Schmutzler; Alfons Meindl; Hermann Brenner; Volker Arndt; Robert Winqvist; Katri Pylkäs; Peter A Fasching; Matthias W Beckmann; Jan Lubinski; Anna Jakubowska; Anna Marie Mulligan; Irene L Andrulis; Rob A E M Tollenaar; Peter Devilee; Loic Le Marchand; Christopher A Haiman; Arto Mannermaa; Veli-Matti Kosma; Paolo Radice; Paolo Peterlongo; Frederik Marme; Barbara Burwinkel; Carolien H M van Deurzen; Antoinette Hollestelle; Nicola Miller; Michael J Kerin; Diether Lambrechts; Giuseppe Floris; Jelle Wesseling; Henrik Flyger; Stig E Bojesen; Song Yao; Christine B Ambrosone; Georgia Chenevix-Trench; Thérèse Truong; Pascal Guénel; Anja Rudolph; Jenny Chang-Claude; Heli Nevanlinna; Carl Blomqvist; Kamila Czene; Judith S Brand; Janet E Olson; Fergus J Couch; Alison M Dunning; Per Hall; Douglas F Easton; Paul D P Pharoah; Sarah E Pinder; Marjanka K Schmidt; Ian Tomlinson; Rebecca Roylance; Montserrat García-Closas; Elinor J Sawyer
Journal:  Breast Cancer Res       Date:  2016-02-17       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.